Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.34)
# 3,476
Out of 4,944 analysts
78
Total ratings
41.77%
Success rate
-16.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $203 | $196.02 | +3.56% | 19 | Aug 8, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $5.25 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $6.20 | - | 11 | Jun 26, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $34.31 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.25 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.07 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $6.80 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.62 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $23.62 | - | 2 | Jan 13, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $9.67 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $8.51 | +135.02% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.22 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.62 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.50 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.61 | +86.34% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $8.71 | +2,425.83% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $0.94 | +434.02% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.96 | +1,838.78% | 1 | Aug 12, 2022 |
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $200 → $203
Current: $196.02
Upside: +3.56%
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $5.25
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.20
Upside: -
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $34.31
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.25
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.07
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.80
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.62
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $23.62
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.67
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $8.51
Upside: +135.02%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.22
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.62
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.50
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.61
Upside: +86.34%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $8.71
Upside: +2,425.83%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $0.94
Upside: +434.02%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.96
Upside: +1,838.78%